Feb 26 2009
Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M Series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. "I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities" said Dr. Robert Bratzler, Executive Chairman of Selecta; he continued "I'm equally pleased by the enormous shareholder value that was created since our initial financing". The proceeds of this financing will be used to expand Selecta's research and development efforts and to advance the lead product candidate through initial clinical evaluation.
Aymeric Sallin, Founder and Managing Director of NanoDimension, said "We're very excited by Selecta's product-platform technology, which is being developed across broad areas of immunology from immune suppression, immune switching, to prophylactic and therapeutic vaccines. This comes at a time of significantly increased business interests in immunomodulation and Selecta's technology, which is at the intersection of materials science and immunology, offers a robust and powerful platform for internal and partnered product development. We are extremely enthusiastic to support the Selecta team in advancing their technology toward commercialization".
Professor Tim Springer, who is among the top cited scientists internationally said "I am delighted to be working with Selecta's scientific founders, advisors, and management to build a world-class company at the convergence of immunobiology and nanotechnology". Professor Springer, who previously founded LeukoSite (acquired by Millennium Pharmaceuticals) continued, "Our immune system has evolved over thousands of years to respond to pathogens which are in essence particles, and what's remarkably compelling is that Selecta is taking advantage of our insights into the working of the immune system to develop first in-class immunomodulatory nanoparticles to improve the lives of patients". Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. "I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities" said Dr. Robert Bratzler, Executive Chairman of Selecta; he continued "I'm equally pleased by the enormous shareholder value that was created since our initial financing". The proceeds of this financing will be used to expand Selecta's research and development efforts and to advance the lead product candidate through initial clinical evaluation.